Minocycline Hydrochloride interactions

Checked as Minocycline in this data source.

Full monograph for Minocycline Hydrochloride Check it against another medicine

Medicines

330 documented

Severity

Mechanism

Medicines documented to interact with Minocycline Hydrochloride, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Acitretin	Major	Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…	25 sources — open the full entry
Clindamycin + Tretinoin	Major	Synergy · Unknown	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…2 documented mechanisms	25 sources — open the full entry
Fluocinolone Acetonide + Hydroquinone + Tretinoin	Major	Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…	25 sources — open the full entry
Iron + Folic Acid + Vitamin A + Vitamin C + Zinc	Major	Absorption · Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…2 documented mechanisms	37 sources — open the full entry
IsotretinoinOral Topical	Major	Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…	25 sources — open the full entry
Leflunomide	Major	Synergy	The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may…	3 sources — open the full entry
Tretinoin (Oral)	Major	Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…	25 sources — open the full entry
Vitamin A	Major	Synergy	Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…	23 sources — open the full entry
Activated Charcoal	Moderate	Absorption	Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects…	25 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…2 documented mechanisms	15 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide + Simethicone	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…2 documented mechanisms	15 sources — open the full entry
Aluminium Oxide + Magnesium Trisilicate	Moderate	Absorption	Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism…	13 sources — open the full entry
Aminophylline	Moderate	Metabolism	Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline…	5 sources — open the full entry
Amoxicillin + Clavulanic Acid	Moderate	Antagonism	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…	8 sources — open the full entry
Amoxicillin Trihydrate	Moderate	Antagonism	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…	8 sources — open the full entry
Ampicillin Sodium	Moderate	Antagonism	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…	8 sources — open the full entry
Atracurium Besilate	Moderate	Synergy	Some drugs may enhance the effects of neuromuscular blocking agents.	2 sources — open the full entry
Benzathine Benzylpenicillin	Moderate	Antagonism	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…	8 sources — open the full entry
Biphasic Insulin Aspart	Moderate	Synergy	Tetracyclines may enhance the hypoglycemic effect of insulin by increasing tissue sensitivity to exogenous insulin.	18 sources — open the full entry
Bismuth Subsalicylate	Moderate	Absorption	INTERVAL: Administration of a bismuth-containing preparation within two to three hours of a tetracycline may significantly decrease serum tetracycline…	6 sources — open the full entry
Calcium Acetate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium acetate + Magnesium carbonate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…2 documented mechanisms	15 sources — open the full entry
Calcium Carbonate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Citrate + Calcitriol	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Gluconate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Lactate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Calcium Phosphate [Milk source] + Vitamin D3	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Carbonyl Iron + Folic Acid	Moderate	Absorption	The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The…	14 sources — open the full entry
Carbonyl Iron + Folic Acid + Zinc Sulfate	Moderate	Absorption	The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The…2 documented mechanisms	21 sources — open the full entry
Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C	Moderate	Absorption	The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The…2 documented mechanisms	21 sources — open the full entry
Cisatracurium Besylate	Moderate	Synergy	Some drugs may enhance the effects of neuromuscular blocking agents.	2 sources — open the full entry
Cloxacillin Sodium	Moderate	Antagonism	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…	8 sources — open the full entry
Cyproterone Acetate + Ethinyl Estradiol	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Digoxin	Moderate	Absorption	Tetracyclines may increase serum levels of orally administered digoxin in about 10% of the population. The mechanism may be related to changes in intestinal…	6 sources — open the full entry
Diphenhydramine Hydrochloride + Zinc Acetate	Moderate	Absorption	INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic…	7 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg 0.03 mg	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Drospirenone + Ethinyl Estradiol + Levomefolate	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Efavirenz	Moderate	Synergy	Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with…	7 sources — open the full entry
Epirubicin Hydrochloride	Moderate	Synergy	The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes…	4 sources — open the full entry
Ergometrine Maleate	Moderate	Others	Limited data suggest that tetracyclines may increase the plasma concentrations and toxicity of ergot alkaloids. The mechanism is unknown, but may be related to…	36 sources — open the full entry
Esomeprazole + Amoxicillin + Clarithromycin	Moderate	Antagonism · Unknown	Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by…2 documented mechanisms	8 sources — open the full entry
Ethinyl Estradiol + Desogestrel0.02 mg 0.03 mg	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Ethinyl Estradiol + Gestodene	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…2 documented mechanisms	105 sources — open the full entry
Ethinyl Estradiol + Lynestrenol0.0375 mg 0.05 mg	Moderate	Absorption	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal…	91 sources — open the full entry
Ferric Maltol	Moderate	Absorption	The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The…	11 sources — open the full entry

Conditions

Conditions in which Minocycline Hydrochloride needs care, as documented in this source.

Colitis
Major
Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.
31 sources
1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
Show all 31 sourcesShow fewer sources
1. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
2. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
3. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
4. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
5. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
6. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
7. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
8. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
9. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
10. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
11. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
12. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
13. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
14. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
15. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
16. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
17. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
18. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
19. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
20. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
21. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
22. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
23. "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):
Esophageal Diseases
Moderate
The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime. Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia. If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.
12 sources
1. Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980): 27
2. Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984): 223
3. Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985): 1009-11
4. Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980): 113-5
5. Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981): 1359-60
6. "Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals (2002):
7. "Product Information. Minocin (minocycline)." Lederle Laboratories (2002):
8. "Product Information. Achromycin (tetracycline)." Lederle Laboratories (2001):
Show all 12 sourcesShow fewer sources
1. "Product Information. Declomycin (demeclocycline)." Lederle Laboratories (2001):
2. Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994): 1185-7
3. Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996): 547-8
4. "Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals (2001):
Kidney Diseases
Moderate
Tetracyclines (except doxycycline) are eliminated by the kidney to various extent. Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance. Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment. Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.
28 sources
1. Lee P, Crutch ER, Morrison RB, et al. "Doxycycline: studies in normal subjects and patients with renal failure." N Z Med J 75 (1972): 355-8
2. Letteri JM, Miraflor F, Tablante V, Siddiqi S "Doxycycline (vibramycin) in chronic renal failure." Nephron 11 (1973): 318-24
3. Whelton A, von Wittenau MS, Twomey TM, et al. "Doxycycline pharmacokinetics in the absence of renal function." Kidney Int 5 (1974): 365-71
4. Mahon WA, Johnson GE, Endrenyi L, et al. "The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function." Scand J Infect Dis 9 (1976): 24-31
5. Heaney D, Eknoyan G "Minocycline and doxycycline kinetics in chronic renal failure." Clin Pharmacol Ther 24 (1978): 233-9
6. Houin G, Brunner F, Nebout T, et al. "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man." Br J Clin Pharmacol 16 (1983): 245-52
7. Shils ME "Renal disease and the metabolic effects of tetracycline." Ann Intern Med 58 (1963): 389-408
8. George CR, Evans RA "Tetracycline toxicity in renal failure." Med J Aust 06/12/71 (1971): 1271-3
Show all 28 sourcesShow fewer sources
1. Whelton A "Tetracyclines in renal insufficiency: resolution of a therapeutic dilemma." Bull N Y Acad Med 54 (1978): 223-36
2. Reddy J "Tetracycline antibiotics should be avoided in patients with renal disease." N Z Med J 94 (1981): 396
3. Carney S, Butcher RA, Dawborn JK, Pattison G "Minocycline excretion and distribution in relation to renal function in man." Clin Exp Pharmacol Physiol 1 (1974): 299-308
4. Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA "Pharmacokinetics of minocycline in renal failure." Antimicrob Agents Chemother 8 (1975): 532-7
5. Saivin S, Houin G "Clinical pharmacokinetics of doxycycline and minocycline." Clin Pharmacokinet 15 (1988): 355-66
6. Sklenar I, Spring P, Dettli L "One-dose and multiple-dose kinetics of minocycline in patients with renal disease." Agents Actions 7 (1977): 369-77
7. Jonas M, Cunha BA "Minocycline." Ther Drug Monit 4 (1982): 137-45
8. Macdonald H, Kelly RG, Allen ES, et al. "Pharmacokinetic studies on minocycline in man." Clin Pharmacol Ther 14 (1973): 852-61
9. Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975): 251-91
10. "Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals (2002):
11. "Product Information. Minocin (minocycline)." Lederle Laboratories (2002):
12. "Product Information. Achromycin (tetracycline)." Lederle Laboratories (2001):
13. Braden GL, Geheb MA, Shook A, Singer I, Cox M "Demeclocycline-induced natriuresis and renal insufficiency: in vivo and in vitro studies." Am J Kidney Dis 5 (1985): 270-7
14. Roth H, Becker KL, Shalhoub RJ, Katz S "Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study." Arch Intern Med 120 (1967): 433-5
15. Miller PD, Linas SL, Schrier RW "Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients." JAMA 243 (1980): 2513-5
16. Kirkpatrick R "Demeclocycline and renal insufficiency." JAMA 239 (1978): 616
17. Oster JR, Epstein M "Demeclocycline-induced renal failure." Lancet 1 (1977): 52
18. Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J "Renal failure associated with demeclocycline in cirrhosis." Ann Intern Med 87 (1977): 195-7
19. "Product Information. Declomycin (demeclocycline)." Lederle Laboratories (2001):
20. "Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals (2001):
Liver Diseases
Moderate
The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.
11 sources
1. Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984): 1491-2
2. Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992): 68-71
3. Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982): 142-6
4. Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975): 251-91
5. "Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals (2002):
6. "Product Information. Minocin (minocycline)." Lederle Laboratories (2002):
7. "Product Information. Achromycin (tetracycline)." Lederle Laboratories (2001):
8. "Product Information. Declomycin (demeclocycline)." Lederle Laboratories (2001):
Show all 11 sourcesShow fewer sources
1. Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996): 1641-3
2. Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997): 143-6
3. "Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals (2001):

Therapeutic duplication

Drug classes that overlap with Minocycline Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

tetracycline-type antibiotics
The recommended maximum number of medicines in the 'tetracycline-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tetracycline-type antibiotics' category.
Example product in the source data (US market): Pylera
tetracycline-type antibiotics
The recommended maximum number of medicines in the 'tetracycline-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tetracycline-type antibiotics' category.
Example product in the source data (US market): Helidac

Medicines

Conditions

Colitis

Esophageal Diseases

Kidney Diseases

Liver Diseases

Therapeutic duplication

tetracycline-type antibiotics

tetracycline-type antibiotics